CAFERGOT
LOE ApproachingNDAORALTABLET
Approved
Nov 1948
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CAFERGOT by Novartis is clinical pharmacology ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. First approved in 1948.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAFERGOT is an oral tablet combining ergotamine (an alpha-adrenergic blocker with serotonin antagonism) and caffeine for acute migraine treatment. Ergotamine acts as a cranial vasoconstrictor with central vasomotor depression, while caffeine enhances vasoconstrictive effects without requiring higher ergotamine doses. The combination targets patients experiencing migraine attacks, particularly those with severe nausea and vomiting.
LOE Approaching
Competitive pressure of 30% signals a mature, crowded market with declining brand relevance; team restructuring toward generic transition or portfolio rebalancing is likely.
Mechanism of Action
CLINICAL PHARMACOLOGY Ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The compound also has the properties of serotonin antagonism. In comparison to…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CAFERGOT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.